Citation Impact
Citing Papers
CTLA-4 Control over Foxp3 + Regulatory T Cell Function
2008 StandoutScienceNobel
Efficacy of Levo-1-Methyl Tryptophan and Dextro-1-Methyl Tryptophan in Reversing Indoleamine-2,3-Dioxygenase–Mediated Arrest of T-Cell Proliferation in Human Epithelial Ovarian Cancer
2009
Differential Antigen Processing by Dendritic Cell Subsets in Vivo
2007 StandoutScienceNobel
Extensive Profiling of the Expression of the Indoleamine 2,3-Dioxygenase 1 Protein in Normal and Tumoral Human Tissues
2014
Selective delivery of β cell antigen to dendritic cells in vivo leads to deletion and tolerance of autoreactive CD8 + T cells in NOD mice
2008 StandoutNobel
Selective blockade of inhibitory Fcγ receptor enables human dendritic cell maturation with IL-12p70 production and immunity to antibody-coated tumor cells
2005 StandoutNobel
Treatment of Autoimmune Neuroinflammation with a Synthetic Tryptophan Metabolite
2005 Science
Tryptophan Catabolism by Indoleamine 2,3-Dioxygenase 1 Alters the Balance of T H 17 to Regulatory T Cells in HIV Disease
2010
An enzymatic toolkit for selective proteolysis, detection, and visualization of mucin-domain glycoproteins
2020 StandoutNobel
PD-1 + regulatory T cells amplified by PD-1 blockade promote hyperprogression of cancer
2019 StandoutNobel
Aire-Dependent Thymic Development of Tumor-Associated Regulatory T Cells
2013 StandoutScienceNobel
A TDO2-AhR Signaling Axis Facilitates Anoikis Resistance and Metastasis in Triple-Negative Breast Cancer
2015
Central Role of IFNγ–Indoleamine 2,3-Dioxygenase Axis in Regulation of Interleukin-12–Mediated Antitumor Immunity
2009
The Combined Effects of Tryptophan Starvation and Tryptophan Catabolites Down-Regulate T Cell Receptor ζ-Chain and Induce a Regulatory Phenotype in Naive T Cells
2006
An Interaction between Kynurenine and the Aryl Hydrocarbon Receptor Can Generate Regulatory T Cells
2010
Induction of Indoleamine 2,3-Dioxygenase in Vascular Smooth Muscle Cells by Interferon-γ Contributes to Medial Immunoprivilege
2007
Kynurenic Acid Is a Potent Endogenous Aryl Hydrocarbon Receptor Ligand that Synergistically Induces Interleukin-6 in the Presence of Inflammatory Signaling
2010
PD-1 expression by tumour-associated macrophages inhibits phagocytosis and tumour immunity
2017 StandoutNature
The IDO–AhR Axis Controls Th17/Treg Immunity in a Pulmonary Model of Fungal Infection
2017
The Indoleamine-2,3-Dioxygenase (IDO) Inhibitor 1-Methyl-D-tryptophan Upregulates IDO1 in Human Cancer Cells
2011
The role of CD28 and cytotoxic T‐lymphocyte antigen‐4 (CTLA‐4) in regulatory T‐cell biology
2006
Elements of cancer immunity and the cancer–immune set point
2017 StandoutNature
Effects of 1-methyltryptophan stereoisomers on IDO2 enzyme activity and IDO2-mediated arrest of human T cell proliferation
2012
Specific subsets of murine dendritic cells acquire potent T cell regulatory functions following CTLA4-mediated induction of indoleamine 2,3 dioxygenase
2004
Ido expression by dendritic cells: tolerance and tryptophan catabolism
2004 Standout
1,2,3-Triazoles as inhibitors of indoleamine 2,3-dioxygenase 2 (IDO2)
2016
Cancer Immunotherapy by Targeting IDO1/TDO and Their Downstream Effectors
2015
IDO-expressing regulatory dendritic cells in cancer and chronic infection
2007
Inhibition of human herpes simplex virus type 2 by interferon γ and tumor necrosis factor α is mediated by indoleamine 2,3-dioxygenase
2004
The biology and management of non-small cell lung cancer
2018 StandoutNature
Dynamic Education of Macrophages in Different Areas of Human Tumors
2012
Up-regulated expression of indoleamine 2,3-dioxygenase 1 in non-Hodgkin lymphoma correlates with increased regulatory T-cell infiltration
2013
An endogenous tumour-promoting ligand of the human aryl hydrocarbon receptor
2011 StandoutNature
Cancer despite immunosurveillance: immunoselection and immunosubversion
2006
Tryptophan metabolites interfere with the Ehrlich reaction used for the measurement of kynurenine
2004
Expression of indoleamine 2,3-dioxygenase by plasmacytoid dendritic cells in tumor-draining lymph nodes
2004
Regulatory T Cells and Immune Tolerance
2008 StandoutNobel
IDO and tolerance to tumors
2003
TGF-β and kynurenines as the key to infectious tolerance
2009
Host Indoleamine 2,3-Dioxygenase: Contribution to Systemic Acquired Tumor Tolerance
2012
Influence of tumour micro-environment heterogeneity on therapeutic response
2013 StandoutNature
Targeting the mechanisms of tumoral immune tolerance with small-molecule inhibitors
2006
The changing landscape of atherosclerosis
2021 StandoutNature
Cinnabarinic acid, an endogenous agonist of type-4 metabotropic glutamate receptor, suppresses experimental autoimmune encephalomyelitis in mice
2014
Microenvironment Tumor Metabolic Interactions Highlighted by qMSI: Application to the Tryptophan-Kynurenine Pathway in Immuno-Oncology
2017
Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase
2003 Standout
Identification of Cinnabarinic Acid as a Novel Endogenous Aryl Hydrocarbon Receptor Ligand That Drives IL-22 Production
2014
The Pathogenesis of Rheumatoid Arthritis
2011 Standout
Regulation of arginase I activity and expression by both PD-1 and CTLA-4 on the myeloid-derived suppressor cells
2008
IDO expression by human B lymphocytes in response to T lymphocyte stimuli and TLR engagement is biologically inactive
2011
Human nutrition, the gut microbiome and the immune system
2011 StandoutNature
Immune Checkpoint Targeting in Cancer Therapy: Toward Combination Strategies with Curative Potential
2015 StandoutNobel
Tolerance, DCs and tryptophan: much ado about IDO
2003
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
2016 Standout
Indoleamine 2,3-dioxygenase pathways of pathogenic inflammation and immune escape in cancer
2014
Indoleamine 2,3-dioxygenase activity and clinical outcome following induction chemotherapy and concurrent chemoradiation in Stage III non-small cell lung cancer
2013
Role of the Kynurenine Metabolism Pathway in Inflammation-Induced Depression: Preclinical Approaches
2016
Tryptophan metabolism: entering the field of aging and age-related pathologies
2013
Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy
2017 Standout
Tolerogenic dendritic cells generated by RelB silencing using shRNA prevent acute rejection
2012
Cardiotonic steroids on the road to anti-cancer therapy
2007
Cancer immunotherapy comes of age
2011 StandoutNature
Expression of Tryptophan 2,3-Dioxygenase and Production of Kynurenine Pathway Metabolites in Triple Transgenic Mice and Human Alzheimer's Disease Brain
2013
IDO1 and IDO2 Non-Synonymous Gene Variants: Correlation with Crohn's Disease Risk and Clinical Phenotype
2014
The blockade of immune checkpoints in cancer immunotherapy
2012 Standout
Antimicrobial and immunoregulatory properties of human tryptophan 2,3‐dioxygenase
2009
Tryptophan degradation in autoimmune diseases
2007
Dioxin and immune regulation
2010
Exosomes facilitate therapeutic targeting of oncogenic KRAS in pancreatic cancer
2017 StandoutNature
Suppression of Th1 differentiation by tryptophan supplementation in vivo
2017
The Foxp3+ regulatory T cell: a jack of all trades, master of regulation
2008
Cancer exome analysis reveals a T-cell-dependent mechanism of cancer immunoediting
2012 StandoutNatureNobel
Establishment of a human indoleamine 2, 3-dioxygenase 2 (hIDO2) bioassay system and discovery of tryptanthrin derivatives as potent hIDO2 inhibitors
2016
Distinct Cellular Mechanisms Underlie Anti-CTLA-4 and Anti-PD-1 Checkpoint Blockade
2017 StandoutNobel
1-l-methyltryptophan is a more effective inhibitor of vertebrate IDO2 enzymes than 1-d-methyltryptophan
2010
Indoleamine 2,3-dioxygenase and tumor-induced tolerance
2007
Tryptophan metabolism as a common therapeutic target in cancer, neurodegeneration and beyond
2019 Standout
Macrophage biology in development, homeostasis and disease
2013 StandoutNature
The interplay between cytokines and the Kynurenine pathway in inflammation and atherosclerosis
2017
IDO inhibits a tryptophan sufficiency signal that stimulates mTOR: A novel IDO effector pathway targeted by D-1-methyl-tryptophan
2012
Indoleamine 2,3-dioxygenase expression and activity in patients with hepatitis C virus-induced liver cirrhosis
2014
The kynurenine to tryptophan ratio as a prognostic tool for glioblastoma patients enrolling in immunotherapy
2015
Metabolites produced by commensal bacteria promote peripheral regulatory T-cell generation
2013 StandoutNature
Indoleamine 2,3 dioxygenase and metabolic control of immune responses
2012
Inhibition of experimental asthma by indoleamine 2,3-dioxygenase
2004
Fuel feeds function: energy metabolism and the T-cell response
2005
Role of the immunosuppressive enzyme indoleamine 2,3-dioxygenase in the progression of ovarian carcinoma
2009
Modulating Tumor Immunology by Inhibiting Indoleamine 2,3-Dioxygenase (IDO): Recent Developments and First Clinical Experiences
2018
CDllc + Cells Modulate Pulmonary Immune Responses by Production of Indoleamine 2,3-Dioxygenase
2003
Indoleamine 2,3-dioxygenase-1 is protective in atherosclerosis and its metabolites provide new opportunities for drug development
2015
Detection of Anti‐HLA Antibodies in Maternal Blood in the Second Trimester to Identify Patients at Risk of Antibody‐Mediated Maternal Anti‐Fetal Rejection and Spontaneous Preterm Delivery
2013
Indoleamine 2,3-dioxygenase–expressing mature human monocyte-derived dendritic cells expand potent autologous regulatory T cells
2009
Important Hydrogen Bond Networks in Indoleamine 2,3-Dioxygenase 1 (IDO1) Inhibitor Design Revealed by Crystal Structures of Imidazoleisoindole Derivatives with IDO1
2015
Role of indoleamine 2,3-dioxygenase in health and disease
2015
Digoxin and other cardiac glycosides inhibit HIF-1α synthesis and block tumor growth
2008 StandoutNobel
Human bone marrow stromal cells inhibit allogeneic T-cell responses by indoleamine 2,3-dioxygenase–mediated tryptophan degradation
2004 Standout
Challenges in the Discovery of Indoleamine 2,3-Dioxygenase 1 (IDO1) Inhibitors
2015
Dendritic cells with TGF-β1 differentiate naïve CD4+CD25−T cells into islet-protective Foxp3+regulatory T cells
2007 StandoutNobel
The Catalytic Asymmetric Mukaiyama–Michael Reaction of Silyl Ketene Acetals with α,β‐Unsaturated Methyl Esters
2017 StandoutNobel
Inhibition of DNA Topoisomerases I and II, and Growth Inhibition of Breast Cancer MCF-7 Cells by Ouabain, Digoxin and Proscillaridin A
2006
Reversal of tumoral immune resistance by inhibition of tryptophan 2,3-dioxygenase
2012
The end of the road for the tryptophan depletion concept in pregnancy and infection
2016
Natural Innate and Adaptive Immunity to Cancer
2011 Standout
Amino acid catabolism: a pivotal regulator of innate and adaptive immunity
2012
CA125 in Ovarian Cancer
2007
Cellular and molecular mechanisms in cancer immune escape: a comprehensive review
2013
The tryptophan catabolite l-kynurenine inhibits the surface expression of NKp46- and NKG2D-activating receptors and regulates NK-cell function
2006
Discovery of IDO1 Inhibitors: From Bench to Bedside
2017
HLA-Binding Properties of Tumor Neoepitopes in Humans
2014
Kynurenine Pathway Enzymes in Dendritic Cells Initiate Tolerogenesis in the Absence of Functional IDO
2006
1-Methyl-Tryptophan Can Interfere with TLR Signaling in Dendritic Cells Independently of IDO Activity
2006
Metal‐Catalyzed Asymmetric Michael Addition in Natural Product Synthesis
2016
Cancer Immunoediting: Integrating Immunity’s Roles in Cancer Suppression and Promotion
2011 StandoutScience
Role of Indoleamine-2,3-Dioxygenase in Alpha/Beta and Gamma Interferon-Mediated Antiviral Effects against Herpes Simplex Virus Infections
2004
Cutting Edge: Induced Indoleamine 2,3 Dioxygenase Expression in Dendritic Cell Subsets Suppresses T Cell Clonal Expansion
2003
Immune Dysregulation by the Rheumatoid Arthritis Shared Epitope
2010
Chemotherapy induces enrichment of CD47 + /CD73 + /PDL1 + immune evasive triple-negative breast cancer cells
2018 StandoutNobel
Chromatographic analysis of tryptophan metabolites
2017
Tryptophan and the immune response
2003
The Janus-Faced Nature of Ido1 in Infectious Diseases: Challenges and Therapeutic Opportunities
2015
Indoleamine 2,3-dioxygenase in cancer: targeting pathological immune tolerance with small-molecule inhibitors
2005
Ligation of B7-1/B7-2 by Human CD4+ T Cells Triggers Indoleamine 2,3-Dioxygenase Activity in Dendritic Cells
2004
Digoxin inhibits neuroblastoma tumor growth in mice.
2005
Indoleamine 2,3-Dioxygenase Is Regulated by IFN-γ in the Mouse Placenta During Listeria monocytogenes Infection
2003
Unique potential of 4-1BB agonist antibody to promote durable regression of HPV + tumors when combined with an E6/E7 peptide vaccine
2015 StandoutNobel
The future of immune checkpoint therapy
2015 StandoutScienceNobel
Characterization of the Fetal Blood Transcriptome and Proteome in Maternal Anti‐Fetal Rejection: Evidence of a Distinct and Novel Type of Human Fetal Systemic Inflammatory Response
2013
Indoleamine 2,3-Dioxygenase Serves as a Marker of Poor Prognosis in Gene Expression Profiles of Serous Ovarian Cancer Cells
2005
Toll-Like Receptor Engagement Enhances the Immunosuppressive Properties of Human Bone Marrow-Derived Mesenchymal Stem Cells by Inducing Indoleamine-2,3-dioxygenase-1 via Interferon-β and Protein Kinase R
2009
Precision glycocalyx editing as a strategy for cancer immunotherapy
2016 StandoutNobel
The Indoleamine 2,3-Dioxygenase Pathway Is Essential for Human Plasmacytoid Dendritic Cell-Induced Adaptive T Regulatory Cell Generation
2008
Tryptophan Catabolism in Cancer: Beyond IDO and Tryptophan Depletion
2012
IDO2: A Pathogenic Mediator of Inflammatory Autoimmunity
2016
Preterm labor: One syndrome, many causes
2014 StandoutScience
IDPi Catalysis
2019 StandoutNobel
T cell exclusion, immune privilege, and the tumor microenvironment
2015 StandoutScience
PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors
2010 StandoutNobel
Tumor indoleamine 2,3-dioxygenase (IDO) inhibits CD19-CAR T cells and is downregulated by lymphodepleting drugs
2015
Tryptophan 2,3-Dioxygenase (TDO) Inhibitors. 3-(2-(Pyridyl)ethenyl)indoles as Potential Anticancer Immunomodulators
2011
Immunological and Nonimmunological Effects of Indoleamine 2,3-Dioxygenase on Breast Tumor Growth and Spontaneous Metastasis Formation
2012
Neoantigens in cancer immunotherapy
2015 StandoutScience
Tolerogenic Dendritic Cells
2003 StandoutNobel
Genetics and biology of pancreatic ductal adenocarcinoma
2016
HIV-1-infected monocyte-derived dendritic cells do not undergo maturation but can elicit IL-10 production and T cell regulation
2004 StandoutNobel
Indoleamine 2,3-Dioxygenase Mediates Cell Type-Specific Anti-Measles Virus Activity of Gamma Interferon
2005
Cancer immunotherapy using checkpoint blockade
2018 StandoutScience
Indoleamine 2,3-dioxygenase is a critical resistance mechanism in antitumor T cell immunotherapy targeting CTLA-4
2013 StandoutNobel
Nitric Oxide-Mediated Regulation of Gamma Interferon-Induced Bacteriostasis: Inhibition and Degradation of Human Indoleamine 2,3-Dioxygenase
2004
N‐Carboxyanhydride Polymerization of Glycopolypeptides That Activate Antigen‐Presenting Cells through Dectin‐1 and Dectin‐2
2018 StandoutNobel
Toward the identification of a tolerogenic signature in IDO-competent dendritic cells
2005
Works of Peter Terness being referenced
Regulation of human auto- and alloreactive T cells by indoleamine 2,3-dioxygenase (IDO)–producing dendritic cells: too much ado about IDO?
2004
IDO1 and IDO2 are expressed in human tumors: levo- but not dextro-1-methyl tryptophan inhibits tryptophan catabolism
2008
The T-cell suppressive effect of bufadienolides: structural requirements for their immunoregulatory activity
2001
Inhibitors of indoleamine-2,3-dioxygenase for cancer therapy: can we see the wood for the trees?
2009
The immunoregulatory role of IDO-producing human dendritic cells revisited
2006
Suppressive dendritic cells as a tool for controlling allograft rejection in organ transplantation: Promises and difficulties
2008
Apoptosis-mediated selective killing of malignant cells by cardiac steroids: maintenance of cytotoxicity and loss of cardiac activity of chemically modified derivatives
2003
Tolerance Signaling Molecules and Pregnancy: IDO, Galectins, and the Renaissance of Regulatory T Cells
2007
Active‐specific immunotherapy of human cancers with the heat shock protein Gp96—revisited
2011
Studying the immunosuppressive role of indoleamine 2,3-dioxygenase: tryptophan metabolites suppress rat allogeneic T-cell responses in vitro and in vivo
2004
Levo- but not dextro-1-methyl tryptophan abrogates the IDO activity of human dendritic cells
2007
Inhibition of Allogeneic T Cell Proliferation by Indoleamine 2,3-Dioxygenase–expressing Dendritic Cells
2002